Drug Report History #257638
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v2-FR | Version v1-EN | |
|---|---|---|
| Language (Changed) | Updated to: French | Was: English |
| Date Updated | 2025-10-31 | 2025-10-31 |
| Drug Identification Number | 02435470 | 02435470 |
| Brand name | FORXIGA | FORXIGA |
| Common or Proper name | Common or Proper name | Common or Proper name |
| Company Name | ASTRAZENECA CANADA INC | ASTRAZENECA CANADA INC |
| Ingredients | DAPAGLIFLOZIN | DAPAGLIFLOZIN |
| Strength(s) | 10MG | 10MG |
| Dosage form(s) | TABLET | TABLET |
| Route of administration | ORAL ORAL | ORAL ORAL |
| Packaging size | Packaging size | Packaging size |
| Additional packaging sizes | ||
| ATC code | A10BK | A10BK |
| ATC description | BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS | BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS |
| Reason for discontinuation | Raw material availability | Raw material availability |
| Anticipated discontinuation date | 2021-01-01 | 2021-01-01 |
| Actual discontinuation date | ||
| Remaining supply date | ||
| Discontinuation status | To be discontinued | To be discontinued |
| Discontinuation decision reversal | no | no |
| Tier 3 Status | No | No |
| Information on remaining supply | ||
| Company comments | ||
| Health Canada comments |